Fusion of engineered albumin with factor IX Padua extends half‐life and improves coagulant activity

The short half‐life of coagulation factor IX (FIX) for haemophilia B (HB) therapy has been prolonged through fusion with human serum albumin (HSA), which drives the neonatal Fc receptor (FcRn)‐mediated recycling of the chimera. However, patients would greatly benefit from further FIX‐HSA half‐life e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Silvia, Aaen, Kristin H., Nilsen, Jeannette, Ferrarese, Mattia, Gjølberg, Torleif T., Bernardi, Francesco, Pinotti, Mirko, Andersen, Jan T., Branchini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Platelets, Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362221/
https://www.ncbi.nlm.nih.gov/pubmed/34109608
http://dx.doi.org/10.1111/bjh.17559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362221/
https://www.ncbi.nlm.nih.gov/pubmed/34109608
http://dx.doi.org/10.1111/bjh.17559

Ejemplares similares